app_store_button

google_play_button

Device Banner Block-copy 894x1036

Astu lugude lõputusse maailma

Loe ja kuula

Medscape

This podcast delivers Dr. John Mandrola's summary and perspective on top news of the week that cardiologists can't miss. This podcast is intended for US health professionals only.

This Week in Cardiology

Listener feedback on non-culprit PCI in STEMI, a major cardiac result in patients on hemodialysis, news on GLP-1 agonists, a dubious stroke trial, and an AHA preview are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I Listener Feedback
 
 Meta-analysis of MI as a surrogate • 
https://pubmed.ncbi.nlm.nih.gov/34694318/ Compare Acute Trial • 
https://www.nejm.org/doi/full/10.1056/NEJMoa1701067 DANAMI-3–PRIMULTI • 
10.1016/S0140-6736(15)60648-1 External Link CULPRIT-SHOCK • 
https://www.nejm.org/doi/full/10.1056/NEJMoa1710261 • 
 
II Huge Cardiac News for Patients with ESRD PISCES article EMBARGOED Till 1130 AM EST
 
 PISCES Trial • 
www.nejm.org/doi/full/10.1056/NEJMoa2513032 REDUCE-IT Trial • 
https://www.nejm.org/doi/full/10.1056/NEJMoa1812792 STRENGTH Trial • 
https://jamanetwork.com/journals/jama/fullarticle/2773120 FISH trial • 
https://jamanetwork.com/journals/jama/fullarticle/1150094 
III Obesity Agents
 
 White House announces deal with Lilly and Novo on GLP-1 drugs • 
https://www.reuters.com/business/healthcare-pharmaceuticals/novo-lilly-shares-rise-trump-obesity-drug-deal-nears-2025-11-06/ 
Amylin Agonists
 
 Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial 
 https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf
 
 Eloralintide Phase 2 Study • 
https://doi.org/10.1016/S0140-6736(25)02155-5 
GLP-1 Comparisons
 
 SURMOUNT-5 Trial • 
https://www.nejm.org/doi/10.1056/NEJMoa2416394 Tirzepatide vs Semaglutide in 10-year CVD Risk Reduction • 
https://doi.org/10.1093/ehjopen/oeaf117 
IV A Problematic Trial in Stroke Care
 
 LAMP trial • 
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2840370 
V AHA Preview
 
AHA 2025: Mandrola's Four Trials to Look For https://www.medscape.com/viewarticle/aha-2025-mandrolas-four-trials-look-2025a1000u80
 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Nov 07, 2025 This Week in Cardiology

Four pillars of cardiology today, stable coronary artery disease, severe aortic stenosis, the evaluation of chest pain, and best therapies for atrial fibrillation are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I Stable CAD Complete vs culprit-only revascularization at time of STEMI
 
 iMODERN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2512918 PRAMI Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1305520 COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775 FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149 PCI Revascularization Strategies After MI https://www.jacc.org/doi/10.1016/j.jacc.2024.04.051 CULPRIT SHOCK Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1710261 How a Meta-Analysis Can Mislead https://www.sensible-med.com/p/how-a-meta-analysis-can-misleadthe 
 
 
II SEVERE Aortic Senosis
 
7-Year PARTNER 3 Results – TAVI vs SAVR
 
 7-year results PARTNER 3 https://www.nejm.org/doi/full/10.1056/NEJMoa2509766 PARTNER 3 at 1 year https://www.nejm.org/doi/10.1056/NEJMoa1814052 PARTNER 3 at 5 years https://www.nejm.org/doi/10.1056/NEJMoa2307447 
III Functional vs Anatomic Assessment in Suspected CAD
 
 10-year follow-up of PROMISE trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2838118 PROMISE Trial https://www.nejm.org/doi/10.1056/NEJMoa1415516 CCTA vs Functional Stress Test – Meta-Analysis https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2655243 
IV ARREST AF 
 
 ARREST AF trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2840225 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Oct 31 2025 This Week in Cardiology

The PREVENT score in hypertension, GLP-1 mechanism of action in cardiovascular disease, CAD type and statin benefit, and the problem with hospitalization endpoints in HF trials are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I Is the PREVENT Calculator Best for Determining CVD Risk? Insights From a Post Hoc Analysis of SPRINT Trial
 
 https://www.medscape.com/viewarticle/prevent-calculator-best-determining-cvd-risk-insights-post-2025a1000svo
 
 PREVENT Calculator https://doi.org/10.1016/j.jacc.2025.07.037 SPRINT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1511939 
II GLP-1 Mechanism of Action in CV Disease
 
 Analysis of SELECT Trial • 
10.1016/S0140-6736(25)01375-3 External Link SELECT trial • 
https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 
III Statins and CAD Phenotype on CTA and Outcomes
 
 Interactions Between Statin Use, CAD Phenotypes on CTA https://www.jacc.org/doi/10.1016/j.jcmg.2025.05.018 Statin Use for Primary Prevention of CVD • 
https://jamanetwork.com/journals/jama/fullarticle/2795522 
IV HHF Endpoints in Heart Failure Trials
 
 The Problem with Hospitalization Endpoints in HF Trials • 
https://onlinelibrary.wiley.com/doi/10.1002/ejhf.70070 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Oct 24 2025 This Week in Cardiology

Another knock against the antiplatelet/anticoagulant combo, polypills in HF, the physical exam of the future, and the problem of underpowered trials that even Bayesian analyses cannot rescue are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I Listener Feedback
 
 Trends Study • 
https://www.heartrhythmjournal.com/article/S1547-5271(11)00496-6/fulltext 
II Another knock against the Antiplatelet/Anticoagulation combination
 
"Antiplatelet Plus Oral Anticoagulant Lowers Stroke, Raises Bleeding Risk" https://www.medscape.com/viewarticle/antiplatelet-plus-oral-anticoagulant-lowers-stroke-raises-2025a1000re0
 
 ATIS-NVAF Trial • 
https://jamanetwork.com/journals/jamaneurology/fullarticle/2839511 AQUATIC trial • 
https://www.nejm.org/doi/abs/10.1056/NEJMoa2507532 
III Polypill for HFrEF
 
 A Multilevel Polypill for Patients With HFrEF • 
https://www.jacc.org/doi/10.1016/j.jacadv.2025.102195 
IV The Physical Exam of the Future
 
 Point-of-Care Ultrasound • 
https://doi.org/10.1016/j.jchf.2025.102707 
V More on Underpowered Trials – GA vs Moderate Sedation in IV stroke
 
 SEGA Trial • 
https://jamanetwork.com/journals/jamaneurology/fullarticle/2839838 Bayesian Analyses of CV Trials • 
https://doi.org/10.1016/j.cjca.2021.03.014 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Oct 17 2025 This Week in Cardiology

GLP-1 use in HFrEF, left atrial posterior wall isolation during AF ablation, peri-device leaks for LAAO, new findings in post-cardiac surgery AF, and imaging before AF ablation are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I. Listener Feedback
 
HYPERION trial https://www.nejm.org/doi/10.1056/NEJMoa2508170
 
ZENITH trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415160
 
II GLP1 Use in HFrEF
 
Effects of GLP-1s in Patients With HFrEF https://doi.org/10.1016/j.jchf.2025.102573
 
FIGHT Study https://jamanetwork.com/journals/jama/fullarticle/2540402
 
FIGHT Study Post-hoc Analysis https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.14862
 
Substudy of EXSCEL Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.041659
 
III LA Posterior Wall Isolation Saga
 
Failure of PW Wall Isolation by PFA with Epicardial Mapping https://doi.org/10.1016/j.jacep.2025.08.017
 
IV Peridevice Leaks After LAAO
 
IMPRESSION LAAC Study https://doi.org/10.1016/j.jacep.2025.08.014
 
V Post Cardiac Surgery AF
 
Monitoring of New-Onset AF After CABG https://jamanetwork.com/journals/jama/fullarticle/2839710
 
PACES trial https://clinicaltrials.gov/study/NCT04045665
 
VI TEE vs ICE Before AF ablation
 
ICE vs TEE Study https://jamanetwork.com/journals/jamacardiology/fullarticle/2839370
 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Oct 10 2025 This Week in Cardiology

Two great stories of translation science leading to beneficial drugs in terrible diseases of the heart and the Sisyphean task of predicting the need for pacing after TAVI are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I Sotatercept
 
 HYPERION Trial https://www.nejm.org/doi/10.1056/NEJMoa2508170 ZENITH Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415160 Evidence report on treatment for PAH https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-on-treatment-for-pulmonary-arterial-hypertension/ PAH Sotatercept Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2503944 
II Acoramidis and ATTR Cardiomyopathy
 
 ATTRIBUTE-CM Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2305434?logout=true ATTRIBUTE-CM Analysis - Substudy https://www.jacc.org/doi/10.1016/j.jacc.2025.09.013 Tafamadis Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1805689 
III Pacing After TAVI
 
 Prophylactic pacemaker after TAVI https://www.jacc.org/doi/10.1016/j.jacep.2025.07.028 PROMOTE study https://doi.org/10.1016/j.hrthm.2024.12.019 Evaluation of ESC criteria on RBBB patients undergoing TAVI https://doi.org/10.1016/j.hrthm.2024.11.030 Editorial on Heart Rhythm journal papers https://www.heartrhythmjournal.com/article/S1547-5271(25)00114-6/abstract 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Oct 03 2025 This Week in Cardiology

A bold trial in valvular heart disease, a CV prevention trial whose message is humility, VTE dogma challenged, more news on oral GLP-1 agonists, and a few public service announcements are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I DOUBLE-CHOICE: Minimalist Approach to TAVI May Be as Good as Standard of Care https://www.medscape.com/viewarticle/double-choice-minimalist-approach-tavi-may-be-good-standard-2025a1000pp7
 
 Patient & Physician Perspectives on CV Risk https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.011837 
II KP Vaccinate Trial
 
 KP Vaccinate Trial https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500208 IAMI trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057042 Increasing Flu Vaccinations in Patients With Chronic Disease https://jamanetwork.com/journals/jama/fullarticle/2824956 MI FREEE Trial https://www.nejm.org/doi/full/10.1056/NEJMsa1107913 
III Hi PRO Trial
 
 Apixaban for Extended Treatment of VTE https://www.nejm.org/doi/full/10.1056/NEJMoa2509426 Recurrent VTE in Patients with Provoked VTE https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/226140 
IV Oral GLP-1 Agonists
 
 ATTAIN 1 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511774 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Sep 26 2025 This Week in Cardiology

More trials at ESC, including PARACHUTE HF, DAPA ACT HF-TIMI 68, AMALFI, and a super-interesting modeling study of when to start oral anticoagulants in AF, are the topics John Mandrola, MD, discusses in this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I PARACHUTE HF
 
First Evidence of Treatment Benefit in Chagas Heart Failure
 
 https://www.medscape.com/viewarticle/first-evidence-treatment-benefit-chagas-heart-failure-2025a1000oem
 
 PARACHUTE-HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021 
II SGLT2i Early Initiation — DAPA ACT HF-TIMI 68 Trial
 
Trial Data Support In-Hospital Initiation of SGLT2 Inhibitors for Heart Failure https://www.medscape.com/viewarticle/trial-data-support-hospital-initiation-sglt2-inhibitors-2025a1000o5q
 
 DAPA ACT HF-TIMI 68 
 https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.076575
 
III AMALFI Trial of AF Screening
 
Remote ECG Screening Ups Atrial Fibrillation Detection 'Modestly' https://www.medscape.com/viewarticle/remote-ecg-screening-ups-atrial-fibrillation-detection-2025a1000myx
 
 AMALFI Trial https://jamanetwork.com/journals/jama/article-abstract/2838482 STROKESTOP Trial https://www.thelancet.com/article/S0140-6736(21)01637-8/fulltext LOOP Trial 10.1016/S0140-6736(21)01698-6 External Link 
IV Finding that Sweet Spot of Stroke Risk Threshold for Starting DOAC therapy
 
 Stroke Risk Threshold for non-Vitamin K Antagonist OAC in AF • 
https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012090 Variations in Rates of Stroke Across Patients With AF • 
https://www.ahajournals.org/doi/10.1161/circulationaha.116.024057 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Sep 19 2025 This Week in Cardiology

More from ESC including: Valvular HD guidelines, a new drug class for HTN, myosin inhibition in HCM, vericiguat, and digoxin are the topic discussed by John Mandrola, MD.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I New European Valvular Heart Disease Guidelines
 
 • 2025 ESC/EACTS Guidelines for the management of valvular heart disease https://doi.org/10.1093/eurheartj/ehaf194
 • Debate: Does Asymptomatic Aortic Stenosis Warrant Early Intervention? https://exp.medscape.com/debates/does-asymptomatic-aortic-stenosis-warrant-early-intervention/
 • Surgical Ablation of Atrial Fibrillation during Mitral-Valve Surgery https://www.nejm.org/doi/full/10.1056/NEJMoa1500528
 • Surgical ablation of atrial fibrillation: a systematic review and meta-analysis https://doi.org/10.1093/europace/eux336
 
II New Drug for Resistant HTN
 
 • Baxdrostat: A 'Game Changer' for Hypertension? https://www.medscape.com/viewarticle/baxdrostat-game-changer-hypertension-2025a1000mz7
 • Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension https://www.nejm.org/doi/full/10.1056/NEJMoa2507109
 • Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension https://www.nejm.org/doi/10.1056/NEJMoa2501440
 
III HCM News at ESC
 
 • New Trials Clarify Role of Myosin Inhibitors for Hypertrophic Cardiomyopathy https://www.medscape.com/viewarticle/new-trials-clarify-role-myosin-inhibitors-hypertrophic-2025a1000myv
 • MAPLE HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2504654
 • SEQUOIA HCM https://www.nejm.org/doi/10.1056/NEJMoa2401424
 • ODYSSEY HCM https://www.nejm.org/doi/full/10.1056/NEJMoa2505927
 
IV Vericiguat at ESC
 
 • New Data Said to Support Vericiguat as Standard Therapy for Heart Failurehttps://www.medscape.com/viewarticle/new-data-said-support-vericiguat-standard-therapy-heart-2025a1000mz9
 • VICTOR https://doi.org/10.1016/S0140-6736(25)01665-4
 • VICTORIA https://www.nejm.org/doi/full/10.1056/NEJMoa1915928
 • An individual participant data analysis of the VICTORIA and VICTOR trials https://doi.org/10.1016/S0140-6736(25)01682-4
 
V More on Digoxin
 
 • RATE AF substudy https://doi.org/10.1002/ejhf.70022
 • Main RATE-AF trial https://jamanetwork.com/journals/jama/fullarticle/2774407
 • Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis https://doi.org/10.1016/S0140-6736(14)61373-8
 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Sep 12 2025 This Week in Cardiology

The big beta-blocker story from ESC, dual pathway therapy with aspirin and OAC, stopping OAC after successful AF ablation, and DANCAVAS II trial are the topics John Mandrola, MD, discusses on this week's podcast.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I Listener Feedback
 
This Week in Cardiology Podcast – August 29 https://www.medscape.com/viewarticle/1002877
 
II The Big Beta-blocker Story from ESC
 
Beta-Blockers Post-MI: A Clear Clinical Message https://www.medscape.com/viewarticle/beta-blockers-post-mi-clear-clinical-message-2025a1000mz0
 
 REBOOT https://www.nejm.org/doi/full/10.1056/NEJMoa2504735 BETAMI-DANBLOCK https://www.nejm.org/doi/abs/10.1056/NEJMoa2505985 REDUCE AMI https://www.nejm.org/doi/10.1056/NEJMoa2401479 CAPITAL RCT https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0199347 Post Hoc Analysis From REBOOT Trial https://eurointervention.pcronline.com/article/effect-of-beta-blocker-withholding-or-withdrawal-after-myocardial-infarction-without-reduced-ejection-fraction-on-ischaemic-events-a-post-hoc-analysis-from-the-reboot-trial Beta-Blockers After MI With Mildly Reduced Ejection Fraction https://doi.org/10.1016/S0140-6736(25)01592-2 CAPRICORN 10.1016/S0140-6736(00)04560-8 External Link BHAT https://jamanetwork.com/journals/jama/fullarticle/370103 ISIS 1 https://pubmed.ncbi.nlm.nih.gov/2873379/ 
III Aspirin and OAC Combination Clearly Dangerous
 
Aspirin Plus Oral Anticoagulants Raises Mortality, Bleeding https://www.medscape.com/viewarticle/aspirin-plus-oral-anticoagulants-raises-mortality-bleeding-2025a1000nam
 
 AQUATIC https://www.nejm.org/doi/full/10.1056/NEJMoa2507532 AFIRE https://www.nejm.org/doi/full/10.1056/NEJMoa1904143 EPIC CAD https://www.nejm.org/doi/10.1056/NEJMoa2407362 OAC-ALONE https://pubmed.ncbi.nlm.nih.gov/30586700/ 
IV Stop or Continue OAC after Successful AF Ablation
 
 ALONE-AF https://jamanetwork.com/journals/jama/fullarticle/2838294 OCEAN trial protocol https://doi.org/10.1016/j.ahj.2017.12.007 
V DANCAVAS II Trial
 
 DANCAVAS II https://doi.org/10.1093/eurheartj/ehaf704 DANCAVAS I https://www.nejm.org/doi/full/10.1056/NEJMoa2208681 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Sep 05 2025 This Week in Cardiology

MRAs in HF with renal dysfunction, coronary autoregulation, the hubris of US doctors, NSTEMI in older patients, survival after STEMI, and new leaders at JACC are discussed by John Mandrola, MD.
 
This podcast is intended for healthcare professionals only.
 
To read a partial transcript or to comment, visit:
 
https://www.medscape.com/twic
 
I Listener Feedback
 
 Combined analysis (Matsumoto) 
II Coronary artery autoregulation with increasing stenosis
 
 NEJM Paper https://www.nejm.org/doi/full/10.1056/NEJMc2402216 
III RECOVER IV Trial
 
 Gregg Stone, MD Tweet https://x.com/GreggWStone/status/1803583552354742416 DANGER-Shock Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2312572 Impella Saves Lives in Cardiogenic Shock, but Patient Selection Key • 
https://www.medscape.com/viewarticle/1000659 
IV NSTEMI Elderly
 
 Main Paper Datamethods https://discourse.datamethods.org/t/random-vs-fixed-effects-meta-analysis/7361 O'Fee Paper https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785560 
V MI Survival
 
Danish Paper https://doi.org/10.1016/j.jacc.2024.04.025
 
You may also like:
 
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
 
Questions or feedback, please contact news@medscape.net

Jun 21 2024 This Week in Cardiology

Loe ja kuula

Muud podcastid, mis võivad sulle meeldida ...